An insider said that over the past decade or so Cipla has become immune to the exits of leaders. There have been no directional change in the long-term strategies. This is a pandemic-hit year, but......
This includes seven products which are pending US Food and Drugs Administration approval (abbreviated new drug application) and an approved product spread across diverse dosage forms. Dr......
Markets closed lower for the third straight day with IT giant TCS leading the fall after its Q2 results missed street expectations while lower dollar revenue guidance from Infosys on Monday also......
Cipla, though late in changing its strategy for international markets, has in recent years taken an inorganic route for expansion. Cipla’s acquisition of the businesses of InvaGen......
Cipla Ltd, India's fourth-largest drugmaker by sales, said on Friday it has agreed to buy two generics businesses in the United States in an all-cash deal worth $550 million to get access to a wide......